Late-onset neutropenia following viral bone marrow depression after rituximab therapy

Annals of Hematology

Volumn 87, Issue 9, 2008, Pages 761-762

  Christopeit, Maximilian ^a   Haak, Ursula ^b   Behre, Gerhard ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b Hospital Martha Maria Halle Dölau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARMUSTINE; COTRIMOXAZOLE; CYTARABINE; ETOPOSIDE; HUMAN IMMUNOGLOBULIN; MELPHALAN; RITUXIMAB;

ADULT; ARTIFICIAL VENTILATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; HOSPITAL READMISSION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LAPAROTOMY; LETTER; MALE; MANTLE CELL LYMPHOMA; MIXED INFECTION; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; PANCYTOPENIA; PARVOVIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEPTIC SHOCK; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEUTROPENIA; TIME FACTORS;

EID: 48649101249     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0455-2     Document Type: Letter

References (4)

1. Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, Takahashi K, Oshima K, Kanda Y, Chiba S, Motokura T, Kurokawa M (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann Oncol 18:364-369
2. Voog E, Morschhauser F, Solal-Celigny P (2003) Neutropenia in patients treated with rituximab. N Engl J Med 348:2691-2694
3. Benyunes M, Multani P, Saunders A (2003) Neutropenia in patients treated with rituximab [response letter]. N Engl J Med 348:2694
4. Hartmann JT, Meisinger I, Kröber SM, Weisel K, Klingel K, Kanz L (2006) Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma. Haematologica 91:16